Proteostasis Therapeutics Inc (NASDAQ:PTI) was up 5.2% during trading on Thursday . The stock traded as high as $1.01 and last traded at $1.01. Approximately 697,315 shares changed hands during trading, a decline of 59% from the average daily volume of 1,696,745 shares. The stock had previously closed at $0.96.
PTI has been the subject of several recent research reports. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Proteostasis Therapeutics in a research note on Monday, March 25th. Zacks Investment Research raised Proteostasis Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research note on Friday, March 15th. ValuEngine raised Proteostasis Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 7th. Finally, Piper Jaffray Companies lowered their price objective on Proteostasis Therapeutics to $5.00 and set an “overweight” rating for the company in a research note on Thursday, May 9th. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. Proteostasis Therapeutics currently has an average rating of “Hold” and an average target price of $9.63.
The company has a debt-to-equity ratio of 0.13, a current ratio of 11.30 and a quick ratio of 11.29.
Proteostasis Therapeutics (NASDAQ:PTI) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.11. Proteostasis Therapeutics had a negative return on equity of 84.01% and a negative net margin of 1,307.84%. The company had revenue of $5.00 million during the quarter, compared to the consensus estimate of $0.80 million. As a group, analysts forecast that Proteostasis Therapeutics Inc will post -1.55 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in PTI. Virtu Financial LLC acquired a new stake in Proteostasis Therapeutics during the 1st quarter valued at approximately $25,000. Jane Street Group LLC increased its position in Proteostasis Therapeutics by 151.5% during the 1st quarter. Jane Street Group LLC now owns 32,092 shares of the company’s stock valued at $40,000 after purchasing an additional 19,333 shares during the period. Bank of Montreal Can increased its position in Proteostasis Therapeutics by 8,649.2% during the 4th quarter. Bank of Montreal Can now owns 15,486 shares of the company’s stock valued at $51,000 after purchasing an additional 15,309 shares during the period. State of Wisconsin Investment Board increased its position in Proteostasis Therapeutics by 85.6% during the 1st quarter. State of Wisconsin Investment Board now owns 49,000 shares of the company’s stock valued at $62,000 after purchasing an additional 22,600 shares during the period. Finally, Hikari Power Ltd acquired a new stake in Proteostasis Therapeutics during the 1st quarter valued at approximately $63,000. 60.15% of the stock is owned by institutional investors and hedge funds.
Proteostasis Therapeutics Company Profile (NASDAQ:PTI)
Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study.
Recommended Story: Dividend Aristocrat Index
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.